Rapidly progressive melanoma differentiation–associated protein 5–positive amyopathic dermatomyositis in an HIV-positive patient

Sharma, Ashutosh; Hudson, Marie; Watters, Kevin; Billick, Robin C.; Fallavolita, Sabrina; Netchiporouk, Elena

doi:10.1016/j.jdcr.2017.01.013

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six of them did not receive calcineurin antagonists as part of the combined therapy with cyclophosphamide with or without mycophenolate 17,[47][48][49]53 . Of these, four patients died 17,48,49 and only two improved 47,53 (Level of evidence 3). According to these data, the expert panel considers that adding rituximab to the combination of glucocorticoid and cyclophosphamide must be taken with caution.…”

Section: Recommendation 3amentioning

confidence: 99%

“…Evidence-based analysis identified several drugs used as rescue therapy in refractory patients with anti-MDA5 positive DM-associated RPILD. Rituximab has been added to the standard immunosuppressive therapy (recommendations 1 and 2) in patients with RPILD impairment 17,48,49,53,[55][56][57][58][59] . Eight out of 13 reported patients died, even though rituximab had been added 17,48,49,55,59 , and 5 improved 17,53,56,57 , although in a single case relapse did not involve the lung 47 (Level of evidence 3).…”

Section: Therapy For the Refractory Patientmentioning

confidence: 99%

See 1 more Smart Citation

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease

Romero-Bueno

Campo

Trallero-Araguás

et al. 2020

Seminars in Arthritis and Rheumatism

142

114

View full text Add to dashboard Cite

show abstract

Section: Recommendation 3amentioning

confidence: 99%

Section: Therapy For the Refractory Patientmentioning

confidence: 99%

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease

Romero-Bueno

Campo

Trallero-Araguás

et al. 2020

Seminars in Arthritis and Rheumatism

142

114

View full text Add to dashboard Cite

show abstract

“…DM is an autoimmune disease primarily affecting skeletal muscle and skin (Waldman, DeWane, and Lu 2020). Clinically, DM is characterized by symmetrical skeletal muscle weakness and cutaneous manifestations including, heliotrope rash, Gottron papules, and Gottron sign (Lundberg et al 2017;Sharma et al 2017). A subset of DM may present as cutaneous stigmata of solid organ malignancy (Qiang et al 2017;Yang et al 2015), whereas all forms may be associated with systemic complications including interstitial lung disease (ILD), oesophageal dysmotility and cardiac disease (Kurasawa et al 2018;Chen et al 2013).…”

Section: Dermatomyositismentioning

confidence: 99%

Novel role of long non-coding RNAs in autoimmune cutaneous disease

Muntyanu

Ridha

et al. 2021

J. Cell Commun. Signal.

Self Cite

View full text Add to dashboard Cite

Systemic autoimmune rheumatic diseases (SARDs) are a heterogeneous group of chronic multisystem inflammatory disorders that are thought to have a complex pathophysiology, which is not yet fully understood. Recently, the role of non-coding RNAs, including long non-coding RNA (lncRNA), has been of particular interest in the pathogenesis of SARDs. We aimed to summarize the potential roles of lncRNA in SARDs affecting the skin including, systemic sclerosis (SSc), dermatomyositis (DM) and cutaneous lupus erythematosus (CLE). We conducted a narrative review summarizing original articles published until July 19, 2021, regarding lncRNA associated with SSc, DM, and CLE. Several lncRNAs were hypothesized to play an important role in disease pathogenesis of SSc, DM and CLE. In SSc, Negative Regulator of IFN Response (NRIR) was thought to modulate Interferon (IFN) response in monocytes, anti-sense gene to X-inactivation specific transcript (TSIX) to regulate increased collagen stability, HOX transcript antisense RNA (HOTAIR) to increase numbers of myofibroblasts, OTUD6B-Anti-Sense RNA 1 to decrease fibroblast apoptosis, ncRNA00201 to regulate pathways in SSc pathogenesis and carcinogenesis, H19X potentiating TGF-β-driven extracellular matrix production, and finally PSMB8-AS1 potentiates IFN response. In DM, linc-DGCR6-1 expression was hypothesized to target the USP18 protein, a type 1 IFN-inducible protein that is considered a key regulator of IFN signaling. Additionally, AL136018.1 is suggested to regulate the expression Cathepsin G, which increases the permeability of vascular endothelial cells and the chemotaxis of inflammatory cells in peripheral blood and muscle tissue in DM. Lastly, lnc-MIPOL1-6 and lnc-DDX47-3 in discoid CLE were thought to be associated with the expression of chemokines, which are significant in Th1 mediated disease. In this review, we summarize the key lncRNAs that may drive pathogenesis of these connective tissue diseases and could potentially serve as therapeutic targets in the future. KeywordsLncRNA • Systemic sclerosis • Cutaneous lupus erythematosus • Dermatomyositis Background Only 1.2% of RNA encodes messenger RNA (mRNA) that is further translated into proteins (Jarroux et al. 2017). Remaining RNA belongs to a class of non-coding RNA (ncRNA) and includes regulatory RNAs such as Anastasiya Muntyanu and Michelle Le have contributed equally to this work.

show abstract

Palmar erythema and palmar papules as predictors for dermatomyositis-related acute/subacute interstitial lung disease: a retrospective study

Liu

Zhou

et al. 2021

Rheumatology

View full text Add to dashboard Cite

Objectives Dermatomyositis (DM)-related acute/subacute interstitial lung disease (A/S-ILD) remains a big therapeutic challenge due to its insidious onset and rapid development. In the present study, we aimed to investigate the association between clinical features of DM and ILD. Methods We retrospectively assessed skin manifestations, muscle damage, laboratory tests, concurrent ILD and malignancy in 207 patients with DM and analyzed the high-risk factors for ILD. Results In the 207 DM patients, 153 patients had ILD, in which 131 had chronic ILD (CILD) and 22 had A/S-ILD. The proportions of mechanic’s hands, palmar papules and muscle weakness, as well as anti-melanoma differentiation-associated gene 5 (MDA5) antibody and lactic dehydrogenase (LDH), alanine aminotransferase (ALT) and ferritin in the ILD group were significantly higher compared with the non-ILD group. The onset age over 56 years, mechanic’s hands and muscle weakness were independent predictive factors for ILD. The proportions of palmar papules, palmar erythema, anti-MDA5 antibody, ALT, aspartate aminotransferase (AST), LDH and erythrocyte sedimentation rate in the A/S-ILD group were higher compared with the CILD group. Palmar erythema and palmar papules were independent predictive factors for A/S-ILD. Palmar papules were positively correlated with anti-MDA5 antibody. Conclusion The onset age over 56 years, mechanic’s hands or muscle weakness predicted the incidence of DM-related ILD, while palmar erythema or palmar papules could predict potential DM-related A/S-ILD.

show abstract

Rapidly progressive melanoma differentiation–associated protein 5–positive amyopathic dermatomyositis in an HIV-positive patient

Cited by 3 publications

References 13 publications

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease

Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease

Novel role of long non-coding RNAs in autoimmune cutaneous disease

Palmar erythema and palmar papules as predictors for dermatomyositis-related acute/subacute interstitial lung disease: a retrospective study

Contact Info

Product

Resources

About